JP2019532617A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532617A5
JP2019532617A5 JP2018568709A JP2018568709A JP2019532617A5 JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5 JP 2018568709 A JP2018568709 A JP 2018568709A JP 2018568709 A JP2018568709 A JP 2018568709A JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical composition
composition according
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532617A (ja
JP7076711B2 (ja
Filing date
Publication date
Priority claimed from US15/201,423 external-priority patent/US10464999B2/en
Application filed filed Critical
Priority claimed from PCT/IB2017/053984 external-priority patent/WO2018007922A2/en
Publication of JP2019532617A publication Critical patent/JP2019532617A/ja
Publication of JP2019532617A5 publication Critical patent/JP2019532617A5/ja
Application granted granted Critical
Publication of JP7076711B2 publication Critical patent/JP7076711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568709A 2016-07-02 2017-06-30 抗トランスサイレチン抗体 Active JP7076711B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/201,423 2016-07-02
US15/201,423 US10464999B2 (en) 2015-01-28 2016-07-02 Anti-transthyretin antibodies
PCT/IB2017/053984 WO2018007922A2 (en) 2016-07-02 2017-06-30 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
JP2019532617A JP2019532617A (ja) 2019-11-14
JP2019532617A5 true JP2019532617A5 (enExample) 2020-08-13
JP7076711B2 JP7076711B2 (ja) 2022-05-30

Family

ID=59506311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568709A Active JP7076711B2 (ja) 2016-07-02 2017-06-30 抗トランスサイレチン抗体

Country Status (3)

Country Link
EP (1) EP3478714A2 (enExample)
JP (1) JP7076711B2 (enExample)
WO (1) WO2018007922A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2018345806A1 (en) 2017-10-06 2020-03-12 Novo Nordisk A/S Anti-transthyretin antibodies
JP7292569B2 (ja) 2017-10-06 2023-06-19 ノボ ノルディスク エー／エス トランスサイレチンを検出する方法
PE20211453A1 (es) 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
MX2022014223A (es) 2020-05-12 2023-04-14 Neurimmune Ag Terapia de combinacion para amiloidosis de la ttr.
CN114106159A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 一种SARS-CoV-2刺突蛋白抗体及其应用
EP4237005A4 (en) * 2020-10-28 2024-10-09 Novo Nordisk A/S ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
JP2025537802A (ja) 2022-11-15 2025-11-20 ニューリミューン アーゲー トランスサイレチン媒介アミロイドーシスを治療又は予防する方法
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
PT1820022E (pt) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Similar Documents

Publication Publication Date Title
JP2019532617A5 (enExample)
JP2019530427A5 (enExample)
JP2019530428A5 (enExample)
JP2018510617A5 (enExample)
JP2018506277A5 (enExample)
JP6234511B2 (ja) アルファシヌクレインを認識するヒト化抗体
JP2020536532A5 (enExample)
TW202126694A (zh) 標靶cd3的抗體、雙特異性抗體及其用途
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
RU2007139953A (ru) Антитела к ccr5 и их применение
JP2017526370A5 (enExample)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
RU2018124859A (ru) Терапевтические антитела к CD47
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
CN104968678A (zh) 靶向epo的抗体的组合物和方法
RU2015118180A (ru) Антитела к бета-амилоиду
JP2018509889A5 (enExample)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP6523243B2 (ja) Ｂａｆｆ及びｂ７ｒｐ１に特異的なタンパク質及びその使用
RS62214B1 (sr) Dkk-1 antitela
RU2018128812A (ru) Четырехвалентные антитела к psgl-1 и их применения